Recent

% | $
Quotes you view appear here for quick access.

NUO THERAPEUTİCS, AŞ Message Board

  • klipken klipken Mar 3, 2013 12:47 PM Flag

    Grafix vs Autologel

    Grafix is Osiris' emerging stem cell-based acute and chronic wound care product. Since one of its main treatment targets is diabetic ulcers, it appears to have direct overlap with CMXI 's autologel. It also has unconditional CMS coverage. Just last week that company announced the launch of a major in-house marketing and sales effort.

    So which company's product is more efficacious and which is cheaper? On both counts, it's hard to tell. Osiris has some fairly straight-forward clinical trial data available with an ongoing Ph4 one covering diabetic foot ulcer healing due to finish this summer. Cytomedix has study data for diabetic wound care out of Japan. Yet it seems CMXI's data is less rigorous, mostly from retrospective registry studies, and hence the CED coverage scheme. To date I have not found any directly comparable data between the two.

    And as for cost, I wasn't able to find any information about what is being charged either through Medicare or other insurance, or on the open market. My guess is PRP in general is cheaper. At this point, though, Osiris seems to be ahead in its efforts to widen Grafix usage while Cytomedix is still bogged-down in getting the CED protocol finalized. I am currently long CMXI and also follow OSIR with no position currently. These two companies have even more overlap due to CMXI's purchase of Aldagen with its stem cell technology focused on heart repair.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • way best in class

    • aotologel is better hands down

      Sentiment: Strong Buy

    • it's a no brainer!

    • no comparison, that's for sure

    • we are the compitition

      Sentiment: Strong Buy

      • 1 Reply to wallyoirish
      • And as for cost, I wasn't able to find any information about what is being charged either through Medicare or other insurance, or on the open market. My guess is PRP in general is cheaper. At this point, though, Osiris seems to be ahead in its efforts to widen Grafix usage while Cytomedix is still bogged-down in getting the CED protocol finalized. I am currently long CMXI and also follow OSIR with no position currently. These two companies have even more overlap due to CMXI's purchase of Aldagen with its stem cell technology focused on heart repair.

    • They must be doing something right.....up 30% today. This would explain why CMXI is in the dog house. OSIR VS CMXI is like Tiger Woods playing Luke Guthrie.

      • 3 Replies to whodontnothat
      • My guess is PRP in general is cheaper. At this point, though, Osiris seems to be ahead in its efforts to widen Grafix usage while Cytomedix is still bogged-down in getting the CED protocol finalized.

        Sentiment: Strong Buy

      • their sales are up to ? .....7 mill. They have more cash on hand and....... they trade on Nasadq. net result is 8$ per share vs .51.......similar companies, but dif indexes. its simple Nasdaq trumps pink sheets. in OSIR vs CMXI its like 16:1

        Sentiment: Buy

      • It's all about management.

        Marty and the boys have now given control of the stock to the finance vampires who will play this long and short for millions of shares below the 55 cent offering price. You could see it happen this morning when some real buying was shot down fast.

        I doubt that management has any understanding of how this toxic financing works, or if they do, they chose to bury their heads in the sand. Potential partners will understand how this works. Smart money knows how this works.

        Management has put this company in a hole that should be familiar to many penny stock investors. While the company may be in better position than ever, shareholders may never got to see the benefits. Vampires will do fine.

        Rule #1 for small company CEOs with no money understanding. Hire a former hedge fund manager to manage your deals. Pay him more than he can make by ripping your company off.

    • I become a bit concerned when insiders sell as they have been doing over the last six months with OSIRIS.

      Net Share Purchase Activity
      Last 6 Months
      Shares Trans
      Purchases N/A 0
      Sales 51,145 3
      Net Shares Purchased
      (Sold) (51,145) 3
      Total Insider Shares Held 24.41M N/A
      % Net Shares Purchased
      (Sold) (0.2%) N/A

      Net Institutional Purchases - Prior Qtr to Latest Qtr
      Shares
      Net Shares Purchased
      (Sold) (503,106)
      % Change in Institutional Shares Held (11.71%)

      Sentiment: Strong Buy

      • 1 Reply to noworrybhappy
      • "The overall clinical experience with individual growth factors and other mediators to accelerate wound healing has not been encouraging. This is not surprising, considering that wound repair is the result of a complex set of interactions among soluble cytokines, formed blood elements, extracellular matrix, and cells. This complexity may explain the growing demand for proven multiple growth factor formulations such as AutoloGel System in the management of chronic wounds"

        also as with Autolgel a patients own cells are used, no doner necessary...in-turn less rejection.

        WIth Grafix there's donor screening, serological testing, bioburden testing and sterility testing is performed on every lot to demonstrate suitability for transplantation. Each lot is tested to confirm cellular viability post this is a bioengineered dressings. However, research shows that mesenchymal stem cells (MSCs) in normal skin play a critical role in the wound healing process. These pass-through codes will allow more Medicare patients and their providers to have greater access to regenerative medicine products.

        .

        Sentiment: Strong Buy

 
CMXI
0.00(0.00%)